Filing Details
- Accession Number:
- 0001368148-21-000103
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-09-17 19:58:10
- Reporting Period:
- 2021-09-15
- Accepted Time:
- 2021-09-17 19:58:10
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1368148 | Athersys Inc / New | ATHX | Pharmaceutical Preparations (2834) | 204864095 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1402610 | J John Harrington | 3201 Carnegie Avenue Cleveland OH 44115-2634 | Exec Vice Pres And Cso | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2021-09-15 | 21,050 | $1.46 | 747,941 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-09-16 | 5,000 | $1.45 | 742,941 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-09-17 | 11,981 | $1.47 | 730,960 | No | 4 | F | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | F | Direct |
Footnotes
- Shares sold pursuant to a predefined Rule 10b5-1 trading plan.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.44 to $1.48, inclusive, in accordance with a previously established Rule 10b5-1 trading plan.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.44 to $1.47, inclusive, in accordance with a previously established Rule 10b5-1 trading plan.
- Shares withheld from the quarterly vesting of annual restricted stock unit awards related to the tax withholding obligation.
- Securities beneficially owned are comprised of (1) 457,194 shares of common stock owned and (2) unvested restricted stock units aggregating 273,766 related to annual awards, which vest quarterly over a four-year period from date of grant.